HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev't; Alex Azar Quoted

Grant Boone
May 27, 2020

Dalhousie University researchers say Canada's first clinical trial for a potential vaccine will start with fewer than 100 people between the ages of 18 and 55.

The paper published in the Lancet reveals the Ad5-nCoV vaccine was well tolerated at all doses with no serious adverse events reported within 28 days of vaccination. Also Read: China's "Batwoman": Coronavirus 'Just Tip of the Iceberg, ' More Pandemics May Arrive "Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global Covid-19 pandemic", said Stanley C. Erck, the president, and CEO of Novavax.

Human testing begins with a small safety trial in healthy volunteers, followed by a larger study to find the correct dose and obtain an early reading of efficacy. If the outcomes are promising, the trial will proceed into its second part, in which a bigger group of contributors in a number of worldwide locations could be examined to judge the security, effectiveness and Covid-19 illness discount capability of the vaccine.

The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults. Washington, D.C, which has not reached the peak of its outbreak, is one likely test site.

A Moderna Inc vaccine, developed in association with the NIH, will be the first to enter large-scale testing in July, and can bind to a vaccine from Britain's Oxford University and AstraZeneca Plc, Collins said.

China Hits Back At New US Securities Regulations
CSRC said it is looking forward to a positive response from the U.S. regulator, and hopes negotiations will be equal and friendly. Subscribe now to stay ahead with the most trusted business news source.

"We want to thank the volunteers who are stepping forward for the benefit of millions of people around the globe, and I sincerely believe we have a vaccine that is going to be very good", Novavax chief scientific officer Doctor Gregory Grenn said, adding he has high hopes.

"A factory in Canada will be contracted to produce the vaccine for the human trial, which is planned for October", said Kiat. BioNTech, in partnership with Pfizer, and Moderna have already begun clinical trials for their vaccines.

Merck has not made any specific announcements on its vaccine program and declined to comment. "The prime minister (Prayuth Chan-ocha) has outlined a policy that we must develop a vaccine and join the world community workforce on this", Suvit told reporters on Saturday. Trials will need to assess if the vaccines cause disease enhancement - a potentially risky side effect in which the vaccine makes the disease worse in some individuals instead of preventing it. Disease enhancement has been seen in animal studies of vaccines developed to fight a close cousin of the virus that causes COVID-19.

"If all the cards fall in the right place and all the stars are aligned, you could definitely get a shot in December or January", said Fauci.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER